Dec
10
2019
On demand

Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies

Meeting the need for innovation in both upstream and downstream AAV viral vector bioprocess technology is a crucial step towards ensuring the continued emergence of the commercial gene therapy sector. A second and closely related one is evolving the analytics required to ensure consistent, robust and cost-effective manufacture. In this webinar, Thermo Fisher Scientific describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.

Attendees find out:

  • How innovation in upstream technology will deliver process robustness and titer enhancement
  • How to optimize and effectively scale up downstream bioprocess workflows in order to capitalize on increased upstream yields
  • What is the latest thinking and innovation in developing the analytics needed to improve both the quality and efficiency of viral vector manufacture for gene therapy
  • New regulatory paradigm for accelerated cell and gene therapy product development.
  • Key points of future focus for further investment and collaboration


Brandon Pence
Vice President & General Manager, Pharma Purification & Analytics at Thermo Fisher Scientific
Richard Snyder
CSO at Thermo Fisher Scientific
Kate Torchilin
Vice President and General Manager, Cell Culture and Cell Therapy at Thermo Fisher Scientific

SPEAKERS

Brandon Pence
Vice President & General Manager, Pharma Purification & Analytics at Thermo Fisher Scientific
Richard Snyder
CSO at Thermo Fisher Scientific
Kate Torchilin
Vice President and General Manager, Cell Culture and Cell Therapy at Thermo Fisher Scientific

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
36
Days
7
Hrs
15
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
14
Days
7
Hrs
15
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
9
Days
7
Hrs
15
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
7
Days
7
Hrs
15
Min
Register

Strategic partnering to enable cell therapy commercialization

J Smith
X de Mollerat du Jeu
Jenessa Smith
Jenessa Smith
Associate Director of Process Development at ArsenalBio
Xavier de Mollerat du Jeu
Xavier de Mollerat du Jeu
Senior Director, R&D, Cell and Gene Therapy at Thermo Fisher Scientific
12 May 2022
Watch now